Definium Therapeutics Target of Unusually High Options Trading (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of some unusual options trading activity on Friday. Stock traders bought 9,041 call options on the stock. This is an increase of 292% compared to the average daily volume of 2,306 call options.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DFTX. Wall Street Zen upgraded Definium Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. Stifel Nicolaus raised their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Piper Sandler restated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Finally, JonesTrading increased their price objective on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $49.23.

Definium Therapeutics Stock Performance

NASDAQ:DFTX traded down $2.46 during midday trading on Friday, hitting $45.99. The company’s stock had a trading volume of 1,045,828 shares, compared to its average volume of 2,330,113. Definium Therapeutics has a fifty-two week low of $7.76 and a fifty-two week high of $49.20. The firm’s 50 day moving average is $28.68 and its 200-day moving average is $21.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a market cap of $4.59 billion, a P/E ratio of -18.47 and a beta of 2.20.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities analysts anticipate that Definium Therapeutics will post -2.29 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Boxer Capital Management LLC purchased a new stake in Definium Therapeutics in the third quarter valued at $1,928,000. Rosalind Advisors Inc. raised its stake in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after buying an additional 330,000 shares during the last quarter. Scientech Research LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter valued at about $286,000. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Definium Therapeutics by 82.0% in the third quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock worth $181,000 after buying an additional 6,903 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.